The future of pharmaceutical investment in the UK hangs in the balance as Eli Lilly, the US-based maker of the popular weight-loss drug Mounjaro, seeks significant changes to drug pricing agreements with the National Health Service (NHS). The company is signaling that a resumption of planned investments, paused last year, is contingent on the UK government agreeing to regularly increase the prices it pays for medicines and dismantle a current rebate scheme. This escalating situation highlights the growing tension between pharmaceutical companies and governments over drug costs and access to innovative treatments.
Patrik Jonsson, president of Eli Lilly’s international business, confirmed the ongoing discussions with UK ministers, expressing optimism about reaching a deal this summer. He told the Financial Times that the talks extend beyond simple price increases, exploring “innovative” pricing models. One such model would tie payments for anti-obesity medications like Mounjaro to demonstrable improvements in patient health, specifically their ability to return to perform – a concept aimed at quantifying the broader economic benefits of treatment.
The pressure on the UK comes amid a broader push from the US pharmaceutical industry for more favorable pricing terms globally. Last year, the UK agreed to the first increase in NHS cost-effectiveness thresholds in 27 years, a move influenced by lobbying from Washington. This adjustment raised the price the NHS is willing to pay for life-extending drugs, increasing the acceptable cost per year of life gained from £20,000 to £30,000 to a range of £25,000 to £35,000.
Investment on Hold: The Impact of Pricing Disputes
Eli Lilly was among several major pharmaceutical companies – including MSD and AstraZeneca – that paused or canceled approximately £25 billion in planned investments in the UK in 2023. Specifically, Eli Lilly put a hold on plans to build a laboratory facility in central London. Jonsson emphasized that the resumption of this investment, and others, is directly tied to a positive outcome from the current negotiations.
“What we would require to notice is actually those goals turning into really a well-defined action plan with interventions and timelines,” Jonsson stated to the FT. He further argued that drug prices in the UK have been “far too low for far too long,” and that even the recent adjustments to the cost-effectiveness threshold haven’t fully restored the market to its previous position. “The threshold can’t be written in stone for another three decades,” he added, signaling a desire for ongoing flexibility in pricing negotiations.
The US-UK Drug Pricing Deal and NHS Funding
The current situation stems, in part, from pressure exerted by former US President Donald Trump on international drug pricing policies. The UK agreed to a deal that will see it pay 25% more for new medicines by 2035. This increase, estimated to potentially reach £9 billion annually, will be funded directly from the NHS budget, rather than the UK Treasury.
Pharmaceutical companies have as well voiced concerns about the existing “rebate” scheme, which requires them to refund a portion of revenue if sales of branded medicines exceed agreed-upon levels. Eli Lilly, along with other industry players, seeks to eliminate this scheme, arguing it disincentivizes innovation and investment. Jonsson believes these payments “should actually get down to zero” over time.
Innovative Agreements and Access to Mounjaro
Despite the pricing disputes, Eli Lilly remains interested in expanding access to its medications in the UK. The company acknowledges that the NHS has implemented some rationing of access to the Mounjaro injection, and is actively exploring alternative agreements. Notably, Eli Lilly is preparing to launch a pill version of Mounjaro later this year, which could potentially offer a more convenient and cost-effective treatment option.
Jonsson highlighted the potential economic benefits of treating obesity, citing data suggesting that intervening can reduce absenteeism and improve workforce productivity. “We have 2.8 million of the UK eligible working population that aren’t coming to work out of sickness,” he noted. “I think there are real opportunities to discuss new models, to work together, and that includes outcome-based agreement.”
Government Response and Future Outlook
A spokesperson for the UK Department of Health and Social Care affirmed the government’s commitment to ensuring access to innovative treatments. They stated that the changes to medicine pricing are intended to “make sure thousands of NHS patients gain faster access to new treatments” and that the UK remains “fully committed to delivering the UK-US pharmaceutical agreement, including the changes to the Nice cost-effectiveness threshold.”
The coming months will be crucial as negotiations between Eli Lilly and the UK government progress. The outcome will not only determine the future of Eli Lilly’s investment plans but also set a precedent for how the UK approaches pharmaceutical pricing and access to innovative medicines going forward. The situation underscores the complex interplay between pharmaceutical innovation, healthcare affordability, and international trade agreements.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical or financial advice.
The next key development will be the outcome of the ongoing talks between Eli Lilly and UK ministers, expected this summer. We will continue to follow this story and provide updates as they become available. Share your thoughts on the future of pharmaceutical pricing in the comments below.
